Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of Dan Li
Introduction
Dan Li is a prominent inventor based in Bethesda, MD, known for his significant contributions to the field of cancer immunotherapy. With a focus on developing advanced therapeutic techniques, he has made strides in the creation of chimeric antigen receptors (CARs) that target specific tumor antigens.
Latest Patents
Dan Li holds a patent for "Chimeric antigen receptors targeting glypican-3 or mesothelin." This patent describes nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt). The CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific, or a mesothelin-specific monoclonal antibody, fused to a CD8α hinge region, a CD8α transmembrane region, a 4-1BB co-stimulatory domain, and a CD3ζ signaling domain. The patent also details isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt. T cells transduced with these CAR constructs can be utilized for cancer immunotherapy.
Career Highlights
Dan Li is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to contribute to groundbreaking research in the field of immunotherapy.
Collaborations
Dan has collaborated with notable colleagues, including Mitchell Ho and Nan Li, to advance research and development in cancer treatment methodologies.
Conclusion
Dan Li's innovative work in developing chimeric antigen receptors represents a significant advancement in cancer immunotherapy. His contributions continue to pave the way for new therapeutic options in the fight against cancer.